Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068584 | 0.89 | PDE10A (0.71) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL12066225 | 0.87 | PDE10A (1.00) | PDE10AMAPTMEN1KMT2A | |
| SCHEMBL7109686 | 0.87 | PDE10A (0.69) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL28001999 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL28001709 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL14795853 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL28524344 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL27964546 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL28236355 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL28236348 | 0.85 | PDE10A (0.67) | PDE10AMAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087674-B | Method for synthesizing quinoxaline compound under catalysis of visible light induced photosensitizer | 河南大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-113087674-A | Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition | 河南大学 | 2021-07-09 | — | — | CN | disclosed |
| CN-108043442-B | Carbon-supported ruthenium nano material, preparation method thereof and application of carbon-supported ruthenium nano material in catalyzing reaction of alcohol and aromatic diamine | 苏州大学 | 2021-03-19 | — | — | CN | disclosed |
| WO-2019078462-A1 | NOVEL HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| EP-3466418-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NuSirt Sciences, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328079-B2 | Process for producing optically active amine | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-07-30 | — | — | US | disclosed |
| WO-2014038666-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | 高砂香料工業株式会社 (JP) | 2014-03-13 | — | — | WO | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2009085879-A2 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210657-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINE | HRH3, HRH1, ATIC | PDE10A 337/4885MAPT 3781/4885MEN1 1200/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | PDE10A 14/4885MAPT 3272/4885MEN1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.